Noetik

Noetik is a private, pre-clinical stage biotech applying frontier AI and machine learning to oncology. The company has built a large-scale, multimodal tumor data collection and uses it to train foundation models capable of simulating the tumor microenvironment. Its platform aims to address key failures in oncology R&D by improving patient stratification for clinical trials, repositioning existing clinical-stage drugs, and discovering novel therapeutic targets. Backed by leading investors, Noetik is led by a seasoned team with deep expertise in computational biology, AI, drug development, and business strategy from companies like Recursion, Genentech, and Roche.

Proprietary AI platform built on one of the world's largest multimodal tumor datasets. It uses foundation models to represent and simulate the full complexity of the tumor microenvironment for target discovery, drug repositioning, and clinical trial patient stratification.

Noetik competes in the crowded AI drug discovery space with public companies like Recursion (RXRX), Exscientia (EXAI), and Insilico Medicine, as well as numerous private peers (e.g., Genesis, Relation Therapeutics). Its differentiation lies in its specific focus on multimodal tumor microenvironment data and cancer immunotherapy, and its team's deep experience in both computational and therapeutic development.